PeerVoice Oncology & Haematology Video

Kim N. Chi, MD, FRCPC / Steven Yip, MD, MSc, FRCPC - Personalizing Treatment Selection, Sequencing, and Future Opportunities for Patients With Advanced Prostate Cancer

Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care

Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?

Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC

Anna Tinker, MD, FRCPC - Maximizing Survival in Advanced or Recurrent Endometrial Cancer: The Evolving Role of Immunotherapy

David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma

Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms

Julie Stakiw, MD, FRCPC - Frailty Assessment and Improved Care in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients

Barbara Melosky, MD, FRCPC - Narrowing the Care Gap in NSCLC With Rare EGFR Alterations: The Next Frontier in Precision Medicine

Stephen Chia, MD, FRCP(C) - Keeping Abreast of the Latest Advances in HER2-Positive Metastatic Breast Cancer Treatment: Clinical Implications for the Canadian Landscape

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Javier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer

Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations

Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?

Stephen Chia, MD, FRCPC - Exploring the Role of Immunotherapy in Triple-Negative Breast Cancer: A Turning Point for a Difficult-to-Treat Disease?

Barbara Melosky, MD, FRCPC - Navigating Recent Updates With Immunotherapy for Advanced NSCLC: Guidance to Optimize Treatment Decisions

D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC

Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans

Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?

Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice

Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations